Risk Factors Update Summary

• Addition of the Wales Medicines Strategy Group to national organizations may impact product development.
• Emphasis on cybersecurity threats, including ransomware attacks, may lead to operational interruptions.
• Planned operations funded until late 2025. This change might result in extended operational stability.
• Change from "vision loss in adults over 65 years of age" to "blindness in patients over 65" may affect market perception.
• Mention of significant disruptions due to Russia's invasion of Ukraine could impact revenue and operations.
• Introduction of stricter data privacy laws, like the CCPA, may increase compliance costs and liability.
• Seeking additional funding through collaboration agreements and financings. This could impact financial flexibility.
• Increase in executive management changes may lead to institutional knowledge loss and business disruptions.
• Focus on potential data breaches and cyber threats could result in financial loss and reputational harm.
• Late 2025 funding estimate based on current activities. This may affect long-term financial planning.
• Changes in manufacturing processes could lead to delays. This might impact production timelines.
• Potential delays in clinical trials due to manufacturing issues. This could affect product development.
• Regulatory compliance challenges with manufacturing facilities. This may lead to operational disruptions.
• Uncertainty in regulatory landscape post-Brexit. This could impact market access and operations.